Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Mar 26, 2023 1:00pm
167 Views
Post# 35361295

RE:RE:RE:keep the enthusiasm in check

RE:RE:RE:keep the enthusiasm in check
Not nonsense as the results of the cornerstone trials cannot be disputed. My main point is that if onc is in negotiations that would it not make sense to sell at a resonable price and remove all doubt for all of the shareholders especially the lifers than to take a CHANCE in the phase 3 while waitng 2-3 more years.
You know the saying bird in the hand. As much as we think we are derisked there is still no guarantee and as much as I too would like more money in my pocket or hopefully at least get my investment back after 22 years would it not make sense to sell even if slightly less than what you are suggesting. 2 Billion is really not unreasonable considering that future trials are not for sure.
<< Previous
Bullboard Posts
Next >>